Stroke +
Familial Hypercholesterolemia (FH)

The carotid arteries, located in the neck, supply blood to the brain. In individuals with FH: LDL particles accumulate in carotid artery walls, plaque forms earlier than in the general population, and carotid intima-media thickness increases. Carotid plaque is a strong predictor of ischemic stroke. Ultrasound studies show that even young adults with untreated FH may demonstrate early carotid artery thickening.

Atherosclerotic plaques are not always stable. In FH: High LDL promotes inflammatory activity inside plaques, plaque caps may weaken, and rupture can trigger clot formation. If a clot forms in the carotid artery or travels to cerebral arteries, it can block blood flow to the brain — causing an ischemic stroke.

Many individuals with FH also have elevated Lipoprotein(a), or Lp(a). Lp(a): promotes clot formation, interferes with clot breakdown, and increases vascular inflammation. Elevated Lp(a) is independently associated with higher stroke risk, especially in younger patients. When FH and high Lp(a) coexist, cerebrovascular risk increases further.

Hypertension is one of the strongest risk factors for stroke. When combined with FH: Endothelial injury worsens, arterial stiffness increases, and plaque rupture risk rises. This dual burden significantly elevates stroke probability.

If FH coexists with diabetes or insulin resistance: Vascular inflammation increases, endothelial dysfunction worsens, and plaque progression accelerates. This metabolic combination can heighten both coronary and cerebrovascular risk.

Although stroke is more common later in life, FH can increase the risk of premature ischemic stroke, particularly in: Individuals with very high LDL, those with elevated Lp(a), and patients with poorly controlled additional risk factors. While stroke risk in FH is generally lower than heart attack risk, it remains clinically significant.

Not all strokes cause dramatic symptoms. In some cases: Small vessel blockages may occur silently, mild cognitive changes may develop, and brain imaging may reveal subclinical infarcts. Early vascular screening can identify risk before major events occur.

Women with FH may be underdiagnosed and undertreated. After menopause: LDL levels often rise further, estrogen protection declines, and stroke risk increases. Awareness during midlife is especially important for women with elevated cholesterol and family history.

Individuals with FH should consider: Lipid panel monitoring, Lipoprotein(a) measurement, blood pressure management, carotid ultrasound (in selected cases), and coronary calcium scoring. Early and aggressive LDL reduction significantly lowers risk of both heart attack and stroke.

Effective management includes aggressive LDL lowering (high-intensity statins, ezetimibe, PCSK9 inhibitors, inclisiran, LDL apheresis in severe cases) and risk factor control (strict blood pressure control, diabetes management, smoking cessation, weight optimization, physical activity). Reducing cumulative LDL exposure — known as "cholesterol-year burden" — is key.